Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES H01C HYPOTHALAMIC HORMONES H01CB Somatostatin and analogues H01CB03 Lanreotide D04666 Lanreotide acetate (JAN/USAN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Antineoplastics, Other Antineoplastics, Miscellaneous Lanreotide D04666 Lanreotide acetate (JAN/USAN) Hormonal Agents, Suppressant (Pituitary) Lanreotide D04666 Lanreotide acetate (JAN/USAN) Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 24 Hormones 249 Miscellaneous 2499 Others D04666 Lanreotide acetate (JAN/USAN) Drug groups [BR:br08330] Hormonal agent DG01588 Somatostatin receptor agonist D04666 Lanreotide acetate Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Somatostatin SSTR2 D04666 Lanreotide acetate (JAN/USAN) <JP/US> SSTR5 D04666 Lanreotide acetate (JAN/USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D04666 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D04666 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D04666